Ratings Medical Facilities Corporation

Equities

DR

CA58457V5036

Market Closed - Toronto S.E. Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
10.86 ^CAD	-0.91%		-1.54%	+20.94%

Apr. 18	Russia accuses Ukraine of shelling medical facilities and of killing medical staff	RE
Apr. 09	Israel purchases 40,000 tents for Rafah evacuation, Israeli media says	RE

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

With a P/E ratio at 11.08 for the current year and 14.68 for next year, earnings multiples are highly attractive compared with competitors.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company does not generate enough profits, which is an alarming weak point.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
MEDICAL FACILITIES CORPORATION	+20.94%	194M	-
AIER EYE HOSPITAL GROUP CO., LTD.	-20.16%	16.21B	B+
BANGKOK DUSIT MEDICAL SERVICES	+4.50%	12.44B	B
IHH HEALTHCARE	+3.98%	11.58B	B+
APOLLO HOSPITALS ENTERPRISE LIMITED	+9.72%	10.79B	B+
ENCOMPASS HEALTH CORPORATION	+23.61%	8.26B	B
RAMSAY HEALTH CARE LIMITED	-2.19%	7.68B	A-
MOUWASAT MEDICAL SERVICES COMPANY	+20.75%	7.2B	D
THE ENSIGN GROUP, INC.	+4.49%	6.67B	B-
GLOBAL HEALTH LIMITED	+50.89%	4.66B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes